【medical-news】Diabetes Obes Metab：胰高血糖素样肽-1受体激动剂在心血管方面是安全的
发布于 2013-07-11 · 浏览 1125 · IP 湖北湖北
这个帖子发布于 11 年零 330 天前，其中的信息可能已发生改变或有所发展。
Aims
New drugs for type 2 diabetes need to demonstrate their cardiovascular safety, due regulatory requirements from the Food and Drug Administration. For this reason, glucagon-like peptide-1 receptor agonists (GLP-1RA) are currently undergoing large-scale, long-term randomized trials specifically designed for cardiovascular outcomes. Aim of the present meta-analysis of randomized clinical trials is the assessment of the effects of GLP-1RA on major cardiovascular events, mortality, and cardiovascular risk factors.
Materials and methods
A meta-analysis was performed including all trials with a duration of at least six months, comparing a GLP-1RA with a non-GLP-1RA agent in type 2 diabetes. Major cardiovascular events (MACE), and mortality were retrieved and combined to calculate Mantel-Haenzel Odds Ratio (MH-OR). Furthermore, data on endpoint systolic and diastolic blood pressure, total and HDL cholesterol, and triglyceride were collected.
Results
of 37 selected trials, 33 reported information on MACE, and 25 reported at least one event. The difference in the incidence of MACE between GLP-1RA and comparators did not reach statistical significance (MH-OR 0.78[0.54-1.13], p?=?0.18). GLP-1RA were associated with a significant reduction in the incidence of MACE in comparisons with placebo and pioglitazone, with a nonsignificant trend toward reduction in DPP4i-controlled studies. No significant effect of GLP-1RA was observed on mortality, although a nonsignificant favorable trend was observed in comparisons with placebo.
Conclusions
The present meta-analysis confirms the cardiovascular safety of GLP1RA, at least in the short term and in low-risk individuals. GLP1RA could have a beneficial effect on the incidence of MACE, at least in comparison with placebo.
New drugs for type 2 diabetes need to demonstrate their cardiovascular safety, due regulatory requirements from the Food and Drug Administration. For this reason, glucagon-like peptide-1 receptor agonists (GLP-1RA) are currently undergoing large-scale, long-term randomized trials specifically designed for cardiovascular outcomes. Aim of the present meta-analysis of randomized clinical trials is the assessment of the effects of GLP-1RA on major cardiovascular events, mortality, and cardiovascular risk factors.
Materials and methods
A meta-analysis was performed including all trials with a duration of at least six months, comparing a GLP-1RA with a non-GLP-1RA agent in type 2 diabetes. Major cardiovascular events (MACE), and mortality were retrieved and combined to calculate Mantel-Haenzel Odds Ratio (MH-OR). Furthermore, data on endpoint systolic and diastolic blood pressure, total and HDL cholesterol, and triglyceride were collected.
Results
of 37 selected trials, 33 reported information on MACE, and 25 reported at least one event. The difference in the incidence of MACE between GLP-1RA and comparators did not reach statistical significance (MH-OR 0.78[0.54-1.13], p?=?0.18). GLP-1RA were associated with a significant reduction in the incidence of MACE in comparisons with placebo and pioglitazone, with a nonsignificant trend toward reduction in DPP4i-controlled studies. No significant effect of GLP-1RA was observed on mortality, although a nonsignificant favorable trend was observed in comparisons with placebo.
Conclusions
The present meta-analysis confirms the cardiovascular safety of GLP1RA, at least in the short term and in low-risk individuals. GLP1RA could have a beneficial effect on the incidence of MACE, at least in comparison with placebo.
最后编辑于 2022-10-09 · 浏览 1125
2 1 1
